Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
In a turbulent market environment, SLRN stock has reached a 52-week low, trading at $1.85. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 7.15, though its market capitalization has contracted to $189.62 million. This price level reflects significant pressure on the company, as investors respond to a range of external and internal factors influencing the stock’s performance. Over the past year, SLRN has seen a dramatic downturn, with the 1-year change data showing a steep decline of -75.68%. This substantial drop underscores the challenges faced by the company in maintaining its market position and investor confidence amidst a shifting economic landscape, with EBITDA at -$373.01 million. While analysts maintain a consensus buy rating with price targets ranging from $3 to $20, detailed analysis and 11 additional key insights are available through the comprehensive Pro Research Report on InvestingPro.
In other recent news, biopharmaceutical company ACELYRIN has ended its License and Collaboration Agreement with Affibody AB, a Swedish biotech firm, according to a recent SEC filing. This termination marks a significant shift in ACELYRIN’s business strategy as the agreement was primarily aimed at the development, commercialization, and manufacture of izokibep, a therapeutic product.
In relation to the company’s ongoing projects, ACELYRIN has presented promising Phase 2 data for its investigational treatment, lonigutamab, for thyroid eye disease (TED) and detailed the design of the Phase 3 LONGITUDE program. The trials, expected to commence in the first quarter of 2025, will assess the safety and efficacy of a 100mg loading dose of lonigutamab followed by a 50mg dose every two weeks.
However, amid these developments, Citi analyst Samantha Semenkow has adjusted the price target for Acelyrin to $3.00, a decrease from the previous $6.00, while maintaining a Neutral rating on the company’s shares. Similarly, H.C. Wainwright analyst Emily Bodnar has also reduced the price target on Acelyrin to $6.00 from the previous $8.00, maintaining a Neutral rating. These adjustments are primarily due to uncertainties regarding the Phase 3 program for lonigutamab.
On a more positive note, Piper Sandler has confirmed its Overweight rating and $20.00 price target for Acelyrin, emphasizing the potential of lonigutamab as a treatment for TED. These recent developments demonstrate the dynamic and evolving nature of ACELYRIN’s operations and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.